IMPROVEMENT OF QUALITY OF LIFE BY TOPICAL TREATMENT OF SCALP PSORIASIS WITH XAMIOL® GEL


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Quality of life (QL) of patients with scalp psoriasis is substantially decreased due to itch and scaling. To control the disease requires long-term therapy; treatment success is greatly dependent on compliance. Patients and methods: In a prospective, non-interventional trial of German dermatological practices 721 patients with scalp psoriasis received Xamiol® gel (calcipotriol 50 mg/g, betamethasone 0,5 mg/g) topically for 4 weeks. Severity was assessed by a physician’s global assessment (PGA) and quality of life by using a scalp-specific questionnaire at the beginning of the study and after 4 weeks of treatment. Results: The mean disease severity of scalp psoriasis (according to PGA) reduced from 4,26 to 2,49 (-41,8%; p < 0,0001) after 4 weeks of treatment and quality of life improved from 10,57 to 3,22 (-69,5%; p < 0,0001). Among patients with pre-treatment, 89,5% of the examinees and 87,9% of dermatologists judged treatment response to Xamiol® gel as better/much better compared to previous therapy. Tolerability of Xamiol® gel was rated good/very good by 98% of the dermatologists and patients, respectively. The use of Xamiol® gel was found easy/ very easy by 90,4% of the patients Conclusions: Due to the major improvement of quality of life and quick onset of improvement together with the high acceptance by most patients, Xamiol® gel may be regarded as the topical treatment of choice for scalp psoriasis

Full Text

Restricted Access

References

  1. Wozel G., Klein E., Mrowietz U. et al. Scalp psoriasis // J. Dtsch Dermatol. Ges. - 2011; 9 (1): 70-4.
  2. Heydendael V., de Borgie C., Spuls P. et al. The burden of psoriasis is not determined by disease severity only // J. Invest. Dermatol. Symp. Proc. - 2004; 9 (2): 131-5.
  3. Dubertret L., Mrowietz U., Ranki A. et al. EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey // Br. J. Dermatol. - 2006; 155 (4): 729-36.
  4. Papp K., Berth-Jones J. et al. Scalp psoriasis: a review of current topical treatment options // J. Eur. Acad. Dermatol. Venereol. - 2007; 21 (9): 1151-60.
  5. Chan C., Van Voorhees A., Lebwohl M. et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation // J. Am. Acad. Dermatol. - 2009; 60 (6): 962-71.
  6. Jemec G., Ganslandt C., Ortonne J. et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial // J. Am. Acad. Dermatol. - 2008; 59 (3): 455-63.
  7. Luger T., Cambazard F., Larsen F. et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis // Dermatology. - 2008; 217 (4): 321-8.
  8. van de Kerkhof P., Hoffmann V., Anstey A. et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial // Br. J. Dermatol. - 2009; 160 (1): 170-6.
  9. Kragballe K., Hoffmann V., Ortonne J. et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial // Br. J. Dermatol. - 2009; 161 (1): 159-66.
  10. Finlay A., Khan G. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use // Clin. Exp. Dermatol. - 1994; 19 (3): 210-6.
  11. Kurth B., Hense H. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Arbeitsgruppe Epidemiologische Methoden der Deutschen Arbeitsgemeinschaft für Epidemiologie (DAE) in Zusammenarbeit mit der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP), Deutschen Region der Internationalen Biometrischen Gesellschaft (DR-IBS). Hoffmann, Stand April 2004. (http://www.gmds.de/publikationen/ empfehlungen.php).
  12. Mrowietz U., Kragballe K., Reich K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus // Arch. Dermatol. Res. -2011; 303 (1): 1-10.
  13. Zaghloul S., Goodfield M. Objective assessment of compliance with psoriasis treatment // Arch. Dermatol. - 2004; 140 (4): 408-14.
  14. Blome C., Simianer S., Purwins S. et al. Time needed for treatment is the major predictor of quality of life in psoriasis // Dermatology. - 2010; 221 (2): 154-9.
  15. Hongbo Y., Thomas C., Harrison M. et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? // J. Invest. Dermatol. - 2005; 125 (4): 659-64.
  16. Ortonne J., Ganslandt C., Tan J. et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial // J. Eur. Acad. Dermatol. Venereol. - 2009; 23 (8): 919-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies